CVS Health: Employers reach break-even point if GLP-1 drugs priced under $350 per month
CVS CVS Health Corp
$89.35 -0.49%
View chart & analysis → - 1CVS Health stated that employers and health insurance sponsors can offset costs if GLP-1 drugs are priced below the $350 monthly break-even point.
- 2An analysis of Aetna insurance claims data found that current GLP-1 drug prices are too high, offsetting medical cost savings and increasing spending.
- 3By 2027, 14% of companies are expected to have discontinued or be planning to discontinue drug coverage, with projections of over 9% in premium increases.
So what's the key point?
CVS Health stated that obesity drug prices must be lower than $350 per month for companies to manage the costs. If drug prices are too high, insurance premiums may rise and companies might stop providing coverage.
Source Reuters · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.